OBJECTIVES: Recent studies demonstrated that prolactin (PRL) has beneficial effects on beta cells for islet transplantation. We examined the effect of human recombinant PRL (rhPRL) supplementation to the culture media to determine its potential use in the context of clinical islet transplantation. MATERIALS AND METHODS: Each human islet isolated from 14 deceased multiorgan donors was cultured in Miami modified media-1 supplemented with or without rhPRL (500 microg/L) for 48 hr. beta-Cell survival and proliferation (BrdU and Ki-67) were determined by laser scanning cytometry. The cytoprotective effects of rhPRL against noxious stimuli were assessed by flow cytometry (tetramethylrhodamine ethyl ester). Cytokine/chemokine and tissue factor productions were measured in vitro, and islet potency was assessed in vivo in diabetic immunodeficient mice. RESULTS: beta-Cell survival during culture was 37% higher in the rhPRL group than in control (P=0.029). rhPRL protected beta cells in vitro from cytokines, Nitric oxide donor, and H2O2. The exposure to rhPRL did not affect human beta-cell proliferation with our protocol. rhPRL treatment did not alter cytokine/chemokine and tissue factor production in vitro or affected human islet functionality in vivo: recipient mice achieved normoglycemia with a comparable tempo, whereas loss of graft function was observed in two of the seven mice in the control group and in none of the rhPRL group (p=n.s.). CONCLUSION: rhPRL supplementation to islet culture media improved human beta-cell-specific survival without altering islet quality. Addition of rhPRL to cultured islets may grant a more viable beta-cell mass in culture. The development of beta-cell cytoprotective strategies will be of assistance in improving islet transplantation outcomes.
OBJECTIVES: Recent studies demonstrated that prolactin (PRL) has beneficial effects on beta cells for islet transplantation. We examined the effect of human recombinant PRL (rhPRL) supplementation to the culture media to determine its potential use in the context of clinical islet transplantation. MATERIALS AND METHODS: Each human islet isolated from 14 deceased multiorgan donors was cultured in Miami modified media-1 supplemented with or without rhPRL (500 microg/L) for 48 hr. beta-Cell survival and proliferation (BrdU and Ki-67) were determined by laser scanning cytometry. The cytoprotective effects of rhPRL against noxious stimuli were assessed by flow cytometry (tetramethylrhodamine ethyl ester). Cytokine/chemokine and tissue factor productions were measured in vitro, and islet potency was assessed in vivo in diabetic immunodeficientmice. RESULTS: beta-Cell survival during culture was 37% higher in the rhPRL group than in control (P=0.029). rhPRL protected beta cells in vitro from cytokines, Nitric oxidedonor, and H2O2. The exposure to rhPRL did not affect human beta-cell proliferation with our protocol. rhPRL treatment did not alter cytokine/chemokine and tissue factor production in vitro or affected human islet functionality in vivo: recipient mice achieved normoglycemia with a comparable tempo, whereas loss of graft function was observed in two of the seven mice in the control group and in none of the rhPRL group (p=n.s.). CONCLUSION: rhPRL supplementation to islet culture media improved human beta-cell-specific survival without altering islet quality. Addition of rhPRL to cultured islets may grant a more viable beta-cell mass in culture. The development of beta-cell cytoprotective strategies will be of assistance in improving islet transplantation outcomes.
Authors: Juan Carlos Lopez-Talavera; Adolfo Garcia-Ocaña; Ian Sipula; Karen K Takane; Irene Cozar-Castellano; Andrew F Stewart Journal: Endocrinology Date: 2003-10-09 Impact factor: 4.736
Authors: John A Goss; Angela P Schock; F Charles Brunicardi; Sarah E Goodpastor; Alan J Garber; George Soltes; Merle Barth; Tatiana Froud; Rodolfo Alejandro; Camillo Ricordi Journal: Transplantation Date: 2002-12-27 Impact factor: 4.939
Authors: Ana Cebrian; Adolfo García-Ocaña; Karen K Takane; Darinka Sipula; Andrew F Stewart; Rupangi C Vasavada Journal: Diabetes Date: 2002-10 Impact factor: 9.461
Authors: Bernhard J Hering; Raja Kandaswamy; James V Harmon; Jeffrey D Ansite; Sue M Clemmings; Tetsuya Sakai; Stephen Paraskevas; Peter M Eckman; Junichiro Sageshima; Masahiko Nakano; Toshiya Sawada; Ippei Matsumoto; Hui J Zhang; David E R Sutherland; Jeffrey A Bluestone Journal: Am J Transplant Date: 2004-03 Impact factor: 8.086
Authors: L Moberg; H Johansson; A Lukinius; C Berne; A Foss; R Källen; Ø Østraat; K Salmela; A Tibell; G Tufveson; G Elgue; K Nilsson Ekdahl; O Korsgren; B Nilsson Journal: Lancet Date: 2002 Dec 21-28 Impact factor: 79.321
Authors: Gopalakrishnan Loganathan; Rajinder K Dawra; Subbiah Pugazhenthi; Zhiguang Guo; Sajjad M Soltani; Alexander Wiseman; Mark A Sanders; Klearchos K Papas; Kumaravel Velayutham; Ashok K Saluja; David E R Sutherland; Bernhard J Hering; A N Balamurugan Journal: Transplantation Date: 2011-12-15 Impact factor: 4.939
Authors: A E Barcala Tabarrozzi; C N Castro; R A Dewey; M C Sogayar; L Labriola; M J Perone Journal: Clin Exp Immunol Date: 2013-02 Impact factor: 4.330
Authors: Yong Wang; Joshua E Mendoza-Elias; Meirigeng Qi; Tricia A Harvat; Sang Joon Ahn; Dongyoung Lee; Diana Gutierrez; Hyojin Jeon; Daniel Paushter; José Oberholzer Journal: Biochem Res Int Date: 2012-05-07
Authors: Lisa Balbach; Henri Wallaschofski; Henry Völzke; Matthias Nauck; Marcus Dörr; Robin Haring Journal: BMC Endocr Disord Date: 2013-03-21 Impact factor: 2.763